# Cholesterol Enzymatic Endpoint

> Active: United States. Medical device record on deviCERTS, compiled from public registries.

- Canonical page: <https://devicerts.com/devices/cholesterol-enzymatic-endpoint-chh>
- Manufacturer: [Randox Laboratories, Ltd.](https://devicerts.com/manufacturers/randox-laboratories-ltd)
- Name in the registry: CHOLESTEROL ENZYMATIC ENDPOINT
- Device class: Class I (US FDA)
- FDA product code: CHH

## Registrations and authorizations

- **510(k)** · FDA 510(k) · United States · K923504 · decision 1994-01-10 · decision SESE · status: Active

## Recalls

- Z-1424-2022 · Class II · terminated · initiated 2022-06-22: Product fails to meet the performance claims quoted on the kit insert: Manual Procedure when calibrating using the standard provided in the kit, the change in absorbance is lower than expected generating internal quality control results high outside range; Cholesterol (CHOL) Instrument Specific Application using the recommended calibration material CAL2351, the product fails to meet its linearity performance claim quoted on the kit inserts. The linearity is reduced by up to -35% however Quality Control results will still fall within assigned ranges. This may lead to delayed results.
- Z-0328-2022 · Class II · terminated · initiated 2021-11-01: When calibrating using the standard provided in the kit, the change in absorbance is lower than expected generating internal quality control results high outside range
- Z-1652-2016 · Class II · terminated · initiated 2016-03-17 · matched through shared submission K923504, may concern other models: Siemens Healthcare Diagnostics has become aware of N-Acetylcysteine (NAC) and Metamizole (Dipyrone) interference with Trinder and Trinder-like reaction assays. Siemens has confirmed that falsely depressed results may occur on samples drawn from patients receiving N-Acetylcysteine (NAC) or Metamizole. NAC is the accepted antidote for acetaminophen toxicity and is justified in patients at signific

## Identifiers

- 510(k) Number: K923504 [FDA 510(k)]
- FDA product code: CHH [FDA 510(k)]

## Classification

- Device class: Class I [FDA 510(k)]
- Regulation: 21 CFR Part 862.1175 [FDA 510(k)]
- Advisory committee: Clinical Chemistry [FDA 510(k)]
- FDA decision: SESE [FDA 510(k)]

## Source and citation

- Cite as: Cholesterol Enzymatic Endpoint, Randox Laboratories, Ltd. deviCERTS medical device catalogue. https://devicerts.com/devices/cholesterol-enzymatic-endpoint-chh (data as of 2026-11-21).
- Data sources: [FDA 510(k)](https://open.fda.gov/apis/device/510k/), [FDA recalls](https://open.fda.gov/apis/device/recall/)
- Registry records last synced: 2026-10-22
- Statuses computed as of: 2026-11-21
- JSON: <https://devicerts.com/devices/cholesterol-enzymatic-endpoint-chh.json>
- Licence: [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/). The deviCERTS layout and text are licensed under CC BY 4.0. Registry data remain under their source terms: U.S. FDA data (openFDA, AccessGUDID) are U.S. public domain; EUDAMED data are subject to the European Commission reuse terms.
- Attribution: DevicErts, https://devicerts.com/devices/cholesterol-enzymatic-endpoint-chh
- Compiled by deviCERTS (devicerts.com) from public medical device registries (EUDAMED, European Commission; U.S. FDA via openFDA; AccessGUDID, U.S. National Library of Medicine). deviCERTS is not an official register and gives no regulatory advice: the record in the registry itself prevails.
